Spyre Therapeutics reported early Phase 2 results for SPY001 in ulcerative colitis, with statistically significant improvements on a disease activity index and remission rates at 12 weeks. The company said the program hit the study’s primary objective in the initial portion of its multi-pronged trial. Spyre positioned SPY001 as an antibody targeting the α4β7 pathway, an immune-inflammatory axis also associated with established IBD biologics. The early safety update included one severe adverse event reported as chest pain in a participant with cardiovascular history, which Spyre said was unrelated to treatment. The next inflection points for investors are placebo-controlled data planned through 2027 and how SPY001 performs in combination arms where differentiation versus existing regimens may be clearest.